RT Book, Section A1 Grimes, Pearl E. A2 Kelly, A. Paul A2 Taylor, Susan C. A2 Lim, Henry W. A2 Serrano, Ana Maria Anido SR Print(0) ID 1161547292 T1 Vitiligo T2 Taylor and Kelly's Dermatology for Skin of Color, 2e YR 2016 FD 2016 PB McGraw-Hill Education PP New York, NY SN 9780071805520 LK accessmedicine.mhmedical.com/content.aspx?aid=1161547292 RD 2024/10/15 AB KEY POINTSVitiligo has an equal incidence in all types of skin color.Given the contrast between the depigmented patches and an individual’s normal skin tones, this disease is most disfiguring for those with darker skin of color.Between 20% and 30% of patients report the disease in first- and second-degree relatives.In vitiligo, an absence of melanocytes is the predominant histologic change.The popular pathogenetic mechanisms for vitiligo include autoimmune, genetic, neural, biochemical, and autocytotoxic causes.Vitiligo patients have an increased frequency of other autoimmune disorders, including Hashimoto thyroiditis, Graves disease, pernicious anemia, and Addison disease.Baseline laboratory tests should include a comprehensive metabolic panel, and thyroid function, antinuclear antibody, and thyroid peroxidase antibody tests.The therapeutic objectives should include both the stabilization and repigmentation of the vitiliginous lesions.The therapies for limited areas of involvement include topical steroids, topical immunomodulators, calcipotriol, and targeted phototherapy.For patients with vitiligo affecting more than 15% to 20% of their body’s surface area, optimal results can be achieved with narrow-band ultraviolet B phototherapy.